Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

By S. Woo, J. Hellstein, J. Kalmar. Annals of Internal Medicine, 2006

1,204 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. (2006, background): “While osteonecrosis of the jaw has been recently associated with bisphosphonate treatment, the vast majority of cases occur in cancer patients receiving frequent intravenous bisphosphonates, and the risk among osteoporosis patients using oral bisphosphonates is very low.(40) That we saw no cases of ”
Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research (2007, background): “● Surgical management: ● Surgical treatment should be conservative or delayed.((12,37,38))”
The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “2 and 50 cases/100,000 person-years, an estimate that appears to double with prolonged duration of bisphosphonate use (> 3 years, median duration 7 years), and decline rapidly with discontinuation [206, 217].”